This is a phase 3 study, experimental, randomized, double blind, four arm parallel group study, lot to lot consistency. The objective of the study is to assess the protectivity of In-House Recombinant Hepatitis B vaccine 28 days after 3 doses immunization, to assess the safety of In-House Recombinant Hepatitis B vaccine, to evaluate immunogenicity and safety in three consecutive batches of In-House Recombinant Hepatitis B vaccine and also evaluate immunogenicity and safety after primary series of investigational product compare to control.
This is a phase 3 study, experimental, randomized, double blind, four arm parallel group study, lot to lot consistency.